Novel Vaccine Technologies and Platforms to Protect from Infectious Diseases

Dear Colleagues,

Vaccines are crucial to maintaining public health, and they have demonstrated cost-effective benefits in protecting both humans and animals from infectious diseases. The majority of vaccines available today rely either on the attenuation or inactivation of infectious agents. However, both techniques have their limitations and potential associated problems. To overcome these problems, scientists have been working on the development of new vaccine technologies and platforms. These include subunit and virus-like particle (VLP) vaccines, synthetic peptide vaccines, polysaccharide, and polysaccharide-conjugated vaccines, bacterial and viral-vector-based vaccines, and DNA- as well as mRNA-based vaccines. Advances in novel vaccine technologies allowed us to quickly respond to the global epidimic caused by SARS-CoV-2; adenovirus-based and mRNA-based vaccines against SARS-CoV-2 were quickly developed and approved in many countries around the world. In the veterinary field, vaccines based on baculovirus or alphavirus vector platform technology can be quickly produced to target agents causing emerging diseases if traditional vaccines are ineffective. This Special Issue of Biologics will cover new research and developments in the area of new vaccine technologies and platforms.

Dr. Alexander Zakhartchouk
Dr. Sams Sadat
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biologics is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.